{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:08:44Z","timestamp":1788883724467,"version":"build-2803163510"},"reference-count":57,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The development of more effective gene therapy strategies for hemophilia B remains essential because results of multiple clinical trials show significant interpatient variability in clinical outcomes, with a fraction of patients (up to 13%) even returning to prophylaxis. Another major challenge in current adeno-associated viral (AAV)\u2013based gene therapy for hemophilia B pertains to dose-dependent vector-related immune responses, requiring immune suppression. We investigated whether combining gene therapy with transgenes encoding extended half-life (EHL) coagulation factors could enhance therapeutic efficacy. AAV vectors encoding a hyperactive factor IX variant R338L (ie, FIX-Padua), genetically fused to a mutant human albumin (FIX-R338L-ALB[QMP]), were administered to both wild-type and hemophilia B mice. These chimeric transgenes were codon-optimized and driven by a hepatocyte-specific promoter. The AAV-FIX-R338L-ALB(QMP) vector demonstrated significantly improved efficacy compared with the control AAV-FIX-R338L vector, resulting in a sustained fourfold and threefold increase in FIX antigen levels and activity, respectively. These increases were consistent with durable correction of the bleeding phenotype. Importantly, immunogenicity or liver toxicity was not increased because no anti-FIX antibodies, alanine transaminase elevations, or liver immune infiltrations were detected after treatment. Furthermore, immune tolerance was achieved in most hemophilia B mice treated with AAV-FIX-R338L-ALB(QMP), even after active immunization with FIX protein and adjuvant, which was found to be mediated by regulatory T cells. In addition, no increase in thrombogenic risk was observed, indicated by stable D-dimer levels. These findings support the potential of FIX-R338L-ALB(QMP) fusion constructs encoding EHL FIX as a promising next-generation gene therapy for hemophilia B.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018891","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:54:22Z","timestamp":1783032862000},"page":"5852-5864","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Increased gene therapy efficacy through the use of extended half-life clotting factors"],"prefix":"10.1182","volume":"10","author":[{"given":"Dries","family":"De Wolf","sequence":"first","affiliation":[{"name":"1Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong Anh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"1Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5117-2169","authenticated-orcid":false,"given":"Nisha","family":"Nair","sequence":"additional","affiliation":[{"name":"1Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangye","family":"Gao","sequence":"additional","affiliation":[{"name":"1Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Anudeep","family":"Bheemsetty","sequence":"additional","affiliation":[{"name":"1Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermira","family":"Samara-Kuko","sequence":"additional","affiliation":[{"name":"1Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinee K.","family":"Chuah","sequence":"additional","affiliation":[{"name":"1Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium"},{"name":"2Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"VandenDriessche","sequence":"additional","affiliation":[{"name":"1Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"17","key":"2026090811324620400_bib1","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N Engl J Med"},{"issue":"23","key":"2026090811324620400_bib2","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2012-05-432591","article-title":"Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice","volume":"120","author":"Cantore","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2026090811324620400_bib3","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood-2012-06-440123","article-title":"The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy","volume":"120","author":"Finn","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2026090811324620400_bib4","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood-2013-10-534032","article-title":"Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy","volume":"123","author":"Nair","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2026090811324620400_bib5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"issue":"8","key":"2026090811324620400_bib6","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2026090811324620400_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/73464","article-title":"Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector","volume":"24","author":"Kay","year":"2000","journal-title":"Nat Genet"},{"issue":"9","key":"2026090811324620400_bib8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2026090811324620400_bib9","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1056\/NEJMoa2414783","article-title":"Sustained clinical benefit of AAV gene therapy in severe hemophilia B","volume":"392","author":"Reiss","year":"2025","journal-title":"N Engl J Med"},{"issue":"21","key":"2026090811324620400_bib10","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"issue":"23","key":"2026090811324620400_bib11","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2026090811324620400_bib12","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"2026090811324620400_bib13","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa2307159","article-title":"Fidanacogene elaparvovec for hemophilia B - a multiyear follow-up study","volume":"392","author":"Rasko","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"2026090811324620400_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2022.12.001","article-title":"First hemophilia B gene therapy approved: more than two decades in the making","volume":"31","author":"Herzog","year":"2023","journal-title":"Mol Ther"},{"issue":"5","key":"2026090811324620400_bib15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1056\/NEJMoa2514332","article-title":"Final analysis of a study of etranacogene dezaparvovec for hemophilia B","volume":"394","author":"Pipe","year":"2026","journal-title":"N Engl J Med"},{"issue":"6","key":"2026090811324620400_bib16","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.ymthe.2025.04.045","article-title":"Current clinical applications of AAV-mediated gene therapy","volume":"33","author":"Byrne","year":"2025","journal-title":"Mol Ther"},{"issue":"17-18","key":"2026090811324620400_bib17","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1089\/hum.2023.112","article-title":"Hemophilia gene therapy: the end of the beginning?","volume":"34","author":"De Wolf","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"9","key":"2026090811324620400_bib18","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/mt.2014.114","article-title":"Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates","volume":"22","author":"Chuah","year":"2014","journal-title":"Mol Ther"},{"issue":"4","key":"2026090811324620400_bib19","first-page":"634","article-title":"Genetic fusion to albumin improves the pharmacokinetic properties of factor IX","volume":"102","author":"Metzner","year":"2009","journal-title":"Thromb Haemost"},{"issue":"2","key":"2026090811324620400_bib20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.17559","article-title":"Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity","volume":"194","author":"Lombardi","year":"2021","journal-title":"Br J Haematol"},{"issue":"17","key":"2026090811324620400_bib21","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1074\/jbc.M117.817064","article-title":"Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway","volume":"293","author":"Chia","year":"2018","journal-title":"J Biol Chem"},{"issue":"3","key":"2026090811324620400_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.20021829","article-title":"The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan","volume":"197","author":"Chaudhury","year":"2003","journal-title":"J Exp Med"},{"issue":"24","key":"2026090811324620400_bib23","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"2026090811324620400_bib24","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"issue":"565","key":"2026090811324620400_bib25","doi-asserted-by":"crossref","first-page":"eabb0580","DOI":"10.1126\/scitranslmed.abb0580","article-title":"An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics","volume":"12","author":"Bern","year":"2020","journal-title":"Sci Transl Med"},{"issue":"10","key":"2026090811324620400_bib26","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood.V90.10.3962","article-title":"A coagulation factor IX-deficient mouse model for human hemophilia B","volume":"90","author":"Lin","year":"1997","journal-title":"Blood"},{"issue":"5","key":"2026090811324620400_bib27","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/hep.24230","article-title":"Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk","volume":"53","author":"M\u00e1trai","year":"2011","journal-title":"Hepatology"},{"issue":"7","key":"2026090811324620400_bib28","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","article-title":"Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver","volume":"110","author":"Mingozzi","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2026090811324620400_bib29","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J Clin Invest"},{"issue":"4","key":"2026090811324620400_bib30","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2007-02-073304","article-title":"Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer","volume":"110","author":"Cao","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2026090811324620400_bib31","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3121\/cmr.3.4.234","article-title":"Tolerance induction by viral in vivo gene transfer","volume":"3","author":"Dobrzynski","year":"2005","journal-title":"Clin Med Res"},{"issue":"12","key":"2026090811324620400_bib32","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1073\/pnas.0508685103","article-title":"Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells","volume":"103","author":"Dobrzynski","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"2026090811324620400_bib33","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1182\/blood-2009-04-214569","article-title":"In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance","volume":"114","author":"Annoni","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2026090811324620400_bib34","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1038\/s41467-024-53378-z","article-title":"Altered drug metabolism and increased susceptibility to fatty liver disease in a mouse model of myotonic dystrophy","volume":"15","author":"Dewald","year":"2024","journal-title":"Nat Commun"},{"issue":"10","key":"2026090811324620400_bib35","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1073\/pnas.0937739100","article-title":"Adeno-associated viruses undergo substantial evolution in primates during natural infections","volume":"100","author":"Gao","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2026090811324620400_bib36","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1128\/JVI.00254-08","article-title":"In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses","volume":"82","author":"Grimm","year":"2008","journal-title":"J Virol"},{"issue":"1","key":"2026090811324620400_bib37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ymthe.2017.09.021","article-title":"Bioengineered AAV capsids with combined high human liver transduction in vivo and unique humoral seroreactivity","volume":"26","author":"Paulk","year":"2018","journal-title":"Mol Ther"},{"issue":"7488","key":"2026090811324620400_bib38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature12875","article-title":"Selection and evaluation of clinically relevant AAV variants in a xenograft liver model","volume":"506","author":"Lisowski","year":"2014","journal-title":"Nature"},{"issue":"9","key":"2026090811324620400_bib39","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/intimm\/10.9.1289","article-title":"Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice","volume":"10","author":"Borvak","year":"1998","journal-title":"Int Immunol"},{"issue":"13","key":"2026090811324620400_bib40","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2007-03-078493","article-title":"A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice","volume":"110","author":"Brown","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2026090811324620400_bib41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"2026090811324620400_bib42","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol Ther"},{"issue":"9","key":"2026090811324620400_bib43","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","article-title":"Addressing high dose AAV toxicity - \u2018one and done\u2019 or \u2018slower and lower\u2019?","volume":"22","author":"Kishimoto","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"19-20","key":"2026090811324620400_bib44","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1089\/hum.2021.29182.bfs","article-title":"Fourth boy dies in clinical trial of Astellas' AT132","volume":"32","author":"Philippidis","year":"2021","journal-title":"Hum Gene Ther"},{"issue":"17-18","key":"2026090811324620400_bib45","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis confirms deaths of two patients treated with gene therapy zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"suppl 1","key":"2026090811324620400_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jvh.13919","article-title":"Hepatitis after gene therapy, what are the possible causes?","volume":"31","author":"Maina","year":"2024","journal-title":"J Viral Hepat"},{"issue":"11","key":"2026090811324620400_bib47","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"2026090811324620400_bib48","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI36891","article-title":"Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors","volume":"119","author":"Pien","year":"2009","journal-title":"J Clin Invest"},{"issue":"4","key":"2026090811324620400_bib49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"issue":"1","key":"2026090811324620400_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/mt.2009.257","article-title":"Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction","volume":"18","author":"Finn","year":"2010","journal-title":"Mol Ther"},{"issue":"12","key":"2026090811324620400_bib51","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2012-10-460733","article-title":"Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells","volume":"121","author":"Martino","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2026090811324620400_bib52","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood.2020009285","article-title":"No CpGs for AAVs?","volume":"137","author":"George","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2026090811324620400_bib53","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2026090811324620400_bib54","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.mt.6300090","article-title":"Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes","volume":"15","author":"Li","year":"2007","journal-title":"Mol Ther"},{"issue":"4","key":"2026090811324620400_bib55","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.mt.6300123","article-title":"Immune responses to AAV capsid: are mice not humans after all?","volume":"15","author":"Herzog","year":"2007","journal-title":"Mol Ther"},{"issue":"1","key":"2026090811324620400_bib56","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/hae.13651","article-title":"Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins","volume":"25","author":"Le Quellec","year":"2019","journal-title":"Haemophilia"},{"issue":"1","key":"2026090811324620400_bib57","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1038\/s41467-022-30102-3","article-title":"Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates","volume":"13","author":"Milani","year":"2022","journal-title":"Nat Commun"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5852\/2541768\/blooda_adv-2025-018891-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5852\/2541768\/blooda_adv-2025-018891-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:33:01Z","timestamp":1788881581000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/5852\/569499\/Increased-gene-therapy-efficacy-through-the-use-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":57,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018891","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,28]]}}}